These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 27843173)
1. Pilot Study on MAGE-C2 as a Potential Biomarker for Triple-Negative Breast Cancer. Zhao Q; Xu WT; Shalieer T Dis Markers; 2016; 2016():2325987. PubMed ID: 27843173 [No Abstract] [Full Text] [Related]
2. The expression of MAGE-C1 and MAGE-C2 in breast cancer and their clinical significance. Hou S; Sang M; Zhao L; Hou R; Shan B Am J Surg; 2016 Jan; 211(1):142-51. PubMed ID: 26321295 [TBL] [Abstract][Full Text] [Related]
3. FOXO3a expression is associated with lymph node metastasis and poor disease-free survival in triple-negative breast cancer. Rehman A; Kim Y; Kim H; Sim J; Ahn H; Chung MS; Shin SJ; Jang K J Clin Pathol; 2018 Sep; 71(9):806-813. PubMed ID: 29588373 [TBL] [Abstract][Full Text] [Related]
4. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt. Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605 [TBL] [Abstract][Full Text] [Related]
5. Expression of NY-ESO-1 in Triple-Negative Breast Cancer Is Associated with Tumor-Infiltrating Lymphocytes and a Good Prognosis. Lee HJ; Kim JY; Song IH; Park IA; Yu JH; Gong G Oncology; 2015; 89(6):337-44. PubMed ID: 26413775 [TBL] [Abstract][Full Text] [Related]
6. Regulator of G protein signaling 20 correlates with clinicopathological features and prognosis in triple-negative breast cancer. Li Q; Jin W; Cai Y; Yang F; Chen E; Ye D; Wang Q; Guan X Biochem Biophys Res Commun; 2017 Apr; 485(3):693-697. PubMed ID: 28237701 [TBL] [Abstract][Full Text] [Related]
7. The Role of Annexin A4 in Triple-Negative Breast Cancer Progression and Its Clinical Application. Zhang ZG; Chen JN; Wang YD; Gao JT; Jin Y Ann Clin Lab Sci; 2016 Sep; 46(5):515-21. PubMed ID: 27650619 [TBL] [Abstract][Full Text] [Related]
8. MiR-128 regulation of glucose metabolism and cell proliferation in triple-negative breast cancer. Xiao M; Lou C; Xiao H; Yang Y; Cai X; Li C; Jia S; Huang Y Br J Surg; 2018 Jan; 105(1):75-85. PubMed ID: 29116653 [TBL] [Abstract][Full Text] [Related]
9. HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis. Abdel-Fatah TM; McArdle SE; Agarwal D; Moseley PM; Green AR; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY Clin Cancer Res; 2016 Feb; 22(4):905-14. PubMed ID: 26240276 [TBL] [Abstract][Full Text] [Related]
10. Correlation of Cystatin E/M with Clinicopathological Features and Prognosis in Triple-Negative Breast Cancer. Li Q; Zheng ZC; Ni CJ; Jin WX; Jin YX; Chen Y; Zhang XH; Chen ED; Cai YF Ann Clin Lab Sci; 2018 Jan; 48(1):40-44. PubMed ID: 29530995 [TBL] [Abstract][Full Text] [Related]
11. S100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype. Ehmsen S; Hansen LT; Bak M; Brasch-Andersen C; Ditzel HJ; Leth-Larsen R Int J Cancer; 2015 Nov; 137(9):2093-103. PubMed ID: 25912829 [TBL] [Abstract][Full Text] [Related]
12. [Expression and clinical significance of MTDH and VEGF in triple-negative breast cancer]. Tan L; Qin H; Piao Y; Liu Z; Han Y; Song F; Xie X Zhonghua Zhong Liu Za Zhi; 2015 Nov; 37(11):827-32. PubMed ID: 26887512 [TBL] [Abstract][Full Text] [Related]
13. MAGE-A is frequently expressed in triple negative breast cancer and associated with epithelial-mesenchymal transition. Wang H; Sang M; Geng C; Liu F; Gu L; Shan B Neoplasma; 2016; 63(1):44-56. PubMed ID: 26639233 [TBL] [Abstract][Full Text] [Related]
14. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer. Chen B; Wang J; Dai D; Zhou Q; Guo X; Tian Z; Huang X; Yang L; Tang H; Xie X J Exp Clin Cancer Res; 2017 May; 36(1):65. PubMed ID: 28494797 [TBL] [Abstract][Full Text] [Related]
15. Elevated expression of HABP1 is a novel prognostic indicator in triple-negative breast cancers. Wang J; Song Y; Liu T; Shi Q; Zhong Z; Wei W; Huang S; Pang D Tumour Biol; 2015 Jun; 36(6):4793-9. PubMed ID: 25794640 [TBL] [Abstract][Full Text] [Related]
16. Expression and prognostic value of MAGE-A9 in laryngeal squamous cell carcinoma. Han L; Jiang B; Wu H; Zhang S; Lu X Int J Clin Exp Pathol; 2014; 7(10):6734-42. PubMed ID: 25400753 [TBL] [Abstract][Full Text] [Related]
17. Clinical implication of leucine zipper/EF hand-containing transmembrane-1 overexpression in the prognosis of triple-negative breast cancer. Wang CA; Liu Q; Chen Y; Liu S; Xu J; Cui X; Zhang Y; Piao L Exp Mol Pathol; 2015 Apr; 98(2):254-9. PubMed ID: 25617527 [TBL] [Abstract][Full Text] [Related]
18. Co-expression of cancer testis antigens and topoisomerase 2-alpha in triple negative breast carcinomas. Mrklić I; Spagnoli GC; Juretić A; Pogorelić Z; Tomić S Acta Histochem; 2014 Jun; 116(5):740-6. PubMed ID: 24560456 [TBL] [Abstract][Full Text] [Related]
19. The Expression of Melanoma-Associated Antigen D2 Both in Surgically Resected and Serum Samples Serves as Clinically Relevant Biomarker of Gastric Cancer Progression. Kanda M; Nomoto S; Oya H; Takami H; Shimizu D; Hibino S; Hashimoto R; Kobayashi D; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y Ann Surg Oncol; 2016 Feb; 23 Suppl 2():S214-21. PubMed ID: 25743330 [TBL] [Abstract][Full Text] [Related]
20. [Effect of high expression of type Ⅰ collagen α1 chain protein on the prognosis of triple negative breast cancer]. Li FF; Fan JJ; Ma BL Zhonghua Zhong Liu Za Zhi; 2020 Feb; 42(2):122-126. PubMed ID: 32135646 [No Abstract] [Full Text] [Related] [Next] [New Search]